Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study

BACKGROUND: The development and rapid uptake of immune checkpoint inhibitors (CPI) has changed the outlook for patients with cancer. However, CPIs have different adverse event (AE) profiles to other systemic therapies, and prompt AE management is essential to assure optimal outcomes. In order to und...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamieson, Liz, Forster, Martin D., Zaki, Kam, Mithra, Sanjena, Alli, Heena, O’Connor, Anne, Patel, Apini, Wong, Ian C. K., Chambers, Pinkie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416581/
https://www.ncbi.nlm.nih.gov/pubmed/32778064
http://dx.doi.org/10.1186/s12885-020-07215-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416581/
https://www.ncbi.nlm.nih.gov/pubmed/32778064
http://dx.doi.org/10.1186/s12885-020-07215-3

Ejemplares similares